Interferon-α Revisited: Individualized Treatment Management Eased the Selective Pressure of Tyrosine Kinase Inhibitors on BCR-ABL1 Mutations Resulting in a Molecular Response in High-Risk CML Patients.

Bone marrow transplantation or ponatinib treatment are currently recommended strategies for management of patients with chronic myeloid leukemia (CML) harboring the T315I mutation and compound or polyclonal mutations. However, in some individual cases, these treatment scenarios cannot be applied. We...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Vaclava Polivkova, Peter Rohon, Hana Klamova, Olga Cerna, Martina Divoka, Nikola Curik, Jan Zach, Martin Novak, Iuri Marinov, Simona Soverini, Edgar Faber, Katerina Machova Polakova
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Public Library of Science (PLoS) 2016-01-01
Serie:	PLoS ONE
Accesso online:	https://journals.plos.org/plosone/article/file?id=10.1371/journal.pone.0155959&type=printable
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!